ProteinQure, the leading start-up in the computational design of peptide drugs, recently announced a significant breakthrough in the fight against Triple-Negative Breast Cancer. The novel Peptide Drug Conjugate, designed by ProteinQure, demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
ProteinQure is an OBIO® member and an alumnus of our BDSP™, CAAP® and WiHI programs.